Background: Inhaled nasal corticosteroid sprays (INS) are often inadequate to treat chronic rhinosinusitis (CRS). The exhalation delivery system with fluticasone (EDS-FLU; XHANCE®) may improve outcomes in CRS by increasing medication delivery to target superior/posterior anatomic sites. This study assessed safety and efficacy of EDS-FLU in a large population with moderate-tosevere CRS with or without nasal polyps (CRSwNP, CRSsNP).
Introduction
Chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP and CRSsNP, respectively) is the second most prevalent chronic health condition in the United States (1) (2) (3) . The economic burden of CRS (direct and indirect costs) was estimated at $22 billion in the United States in 2014 (4) . CRS is associated with 4 cardinal defining symptoms: nasal con-gestion/obstruction, rhinorrhea, facial pain/pressure, and reduction/loss of smell (5, 6) . Extra-sinonasal manifestations, including headache, sleep dysfunction, disordered mood (notably depression), and exacerbations of asthma and pulmonary disease, are common (5) (6) (7) (8) . CRS is also associated with a large disease burden (9, 10) . Harm to quality of life (QoL) has been measured and is of similar magnitude to other serious chronic diseases such as congestive heart failure, chronic obstructive pulmonary disease, and Parkinson's (9) . CRS is a syndrome characterized by inflammation affecting superior and posterior intranasal anatomical regions difficult to reach with conventional nasally inhaled topically-acting steroids (11) (12) (13) . Inflammation at these sites can impair normal sinus and nasal cavity drainage and ventilation (14, 15) . Complicating matters further are impaired mucociliary clearance, abnormal ventilation, and poor drainage of narrow crevices in the upper posterior nasal cavity and sinuses (11) . Nasal polyps (NP), commonly originating in the osteomeatal complex (OMC) region, can further exacerbate physical obstruction of paranasal sinus ventilation and clearance, and produce a variety of inflammatory cytokines (16) (17) (18) .
Oral corticosteroids are often effective in alleviating both symptoms and objective signs of CRS, but repeated or chronic use is constrained by many potentially serious risks, including avascular necrosis, infection, and venous thromboembolism (19) (20) (21) (22) . Nevertheless, this observation shows that the molecular activity of corticosteroids is often effective in addressing CRS. To attempt to achieve this efficacy without systemic risk, most CRS treatment guidelines recommend first-line therapy with nasally administered, topically acting corticosteroids (5, 6) . Topically acting corticosteroids are most often delivered by inhaled nasal spray.
Target anatomic sites in CRS are the areas through which sinuses drain and ventilate, including the middle meatus and OMC (located above the inferior turbinate, under the middle turbinate, and behind the uncinate process). Unfortunately, conventional nasal sprays often do not efficiently deposit the locally acting drug in disease sites beyond the nasal valve area, notably failing to reach the middle meatus/OMC, and are associated with drug loss to non-target sites (e.g., anterior "drip-out, " or posterior loss to swallowing) (23) (24) (25) (26) . Poor targeting with conventional inhaled nasal sprays is believed to result in inadequate symptom control, limited polyp reduction when polyps are present, and annoying side effects (e.g., dysgeusia, loss of drug to drip-out or into the throat) (21) (22) (23) (27) (28) (29) . The inadequate efficacy of conventional nasal spray steroids for treating CRS has been noted by multiple authors, and a large majority of patients with CRS report frustration with efficacy and low treatment satisfaction with these inhalation products (27) (28) (29) (30) . Several non-conventional approaches for corticosteroid delivery (typically at significantly higher doses than used for allergic rhinitis) have been studied, although none have previously been approved by the U.S. Food and Drug Administration (FDA).
These include nasal drops and high-volume irrigation with a mixture of saline and a liquid steroid suspension. Some of these approaches may be effective; however, administration can be time consuming, typically relies on special head positions and procedures that can be difficult and uncomfortable for patients to consistently adhere to, and dose control may be challenging (31) (32) (33) . With irrigation in particular, 97.5% of the drug exits the nose or is swallowed, and patients may be bothered by post-irrigation rhinorrhea (31, 32) . These factors create significant challenges to long-term compliance, with negative ramifications for efficacy (23, 26) .
The FDA-approved exhalation delivery system with fluticasone (EDS-FLU; XHANCE®) uses a novel exhalation delivery mechanism to deposit steroid superiorly and posteriorly in target regions affected by chronic inflammation in CRS, including the middle meatus/OMC (Figure 1 ) (36, 37) . EDS-FLU comprises both an exhalation delivery system and a high-potency, low-bioavailability, topical corticosteroid (fluticasone) in an alcohol-and fragrance-free liquid formulation at a higher concentration than conventional over-the-counter and prescription inhaled nasal spray products (37) (38) (39) (40) (41) . EDS-FLU uses a novel mechanism and exposes significantly different anatomic locations to active medication compared with conventional inhaler sprays and has been studied extensively. Evidence from multiple published studies, including a randomized pharmacokinetic study, two large randomized controlled trials (RCTs), and one long-term prospective, single-arm study, have characterized its efficacy and safety and demonstrated that EDS-FLU is not bioequivalent to comparable doses of conventional fluticasone nasal spray (Flonase®) (37) (38) (39) (40) (41) . The objective of this study was to evaluate patient experience by assessing the safety and efficacy of EDS-FLU 372 µg twice daily (BID) in a large and relatively heterogenous population with moderate-to-severe CRSwNP or CRSsNP. This study expands on prior knowledge by prospectively evaluating the highest dose of EDS-FLU in a substantially larger population, permitting evaluation of less common events and expanding the generalizability of results. Efficacy was measured by 22-item Sino-Nasal Outcome Test (SNOT-22), a widely used, disease-specific, patient-reported instrument assessing QoL, functioning, and symptoms. is validated in CRS, with each item scored from 0 (no problem) to 5 (as bad as can be), producing a total scoring range of 0 to 110 (43) . The minimal clinically important difference (MCID) has been reported to be 8.9-12 (44, 45) . Additionally, in participants with NP at baseline, a modified Lildholdt NP grading scale was used to assess change in polyp grade with treatment. Polyp assessment with this scale is not a measure of total polyp mass or bulk; rather, it non-linearly evaluates extent of observable polyp tissue in a single dimension (vertical) against fixed anatomic landmarks. In this study, possible scores ranged from 0 (no polyps observed) to 3 (polyp tissue extends below the inferior border of the inferior turbinate) on each side (46) . Surgical-indica-1 had to be congestion or rhinorrhea, lasting ≥3 months, and receive a diagnosis from a specialist after endoscopic examination. Defining symptoms included nasal congestion/obstruction, rhinorrhea, facial pain/pressure, and reduction/loss of smell.
Materials and methods
Participants with comorbid asthma or COPD had to be stable at entry (no exacerbations within 3 months of screening). Inhaled pulmonary corticosteroid use was limited to stable doses ≤1000 µg/day of beclomethasone (or equivalent) for at least 3 months prior to screening. Treatment with any other intranasal corticosteroid or an orally inhaled corticosteroid was not permitted, except for the above-mentioned drugs and doses for asthma and COPD.
Exclusion criteria included known nasal septum perforation; >1 episode of frank nasal bleeding in the month prior to screening; evidence of significant mucosal injury, ulceration, or erosion at screening; history of sinonasal surgery within 6 months; or planned sinonasal surgery during the study period.
A pretreatment phase of up to 7 days preceded a screening visit.
Following screening and selection, all participants received EDS-FLU 372 µg BID. Because an objective of this study was to assess safety in a broad CRS population with and without polyps, all patients received the highest dose evaluated in dose-ranging RCTs (39, 40) . Safety was proactively assessed at Months 1, 2, and 3:
visits at Months 1 and 3, and contact at Month 2. Adverse events Figure 1 . Exhalation Delivery System (EDS) mechanism of action. The EDS has a flexible mouthpiece and a sealing nosepiece. The nosepiece is uniquely shaped to seal at the nostril in order to transfer pressure from the oral cavity, avoid obstruction by compression of soh tissue, and stent/expand the upper part of the nasal valve. Exhalation through the EDS: 1) creates an airtight seal of the soft palate, isolating the nose from the mouth and lungs , 2) transfers proportional pressure into the nose, and 3) helps "float" medication around obstructions to deposit in high/deep sites throughout the nasal labyrinth, such as the OMC. "Positive-pressure" delivery expands passages narrowed by inflammation (versus negative pressure delivery, "sniffing").
The transferred pressure is proportional to varying exhalation force, counterbalancing pressure across the soh palate. This assures a patent communication behind the nasal septum, allowing air to escape through the opposite nostril. Use is simple and quick. A patient inserts the nosepiece into one nostril and starts blowing through the mouthpiece. This elevates and seals the soft palate, as with inflating a balloon, separating the oral and nasal cavities. The patient completes use by pressing the bottle to actuate. This causes a coordination-reducing valve to release the exhaled breath concurrently with aerosol spray in a "burst" of naturally humidified air that escapes through the contralateral nostril after depositing the drug particles (59) . tor assessment criteria for participants with CRSwNP required all the following: moderate congestion for ≥3 months; at least moderate symptoms despite use of topical steroids at conventional doses for ≥6 weeks; at least moderate symptoms despite use (or previous use) of saline lavage for ≥6 weeks; and NP grade ≥2 in at least 1 nostril. Criteria for participants with CRSsNP required all of the following: moderate severity of ≥2 core symptoms (congestion/blockage, nasal discharge, facial pain/pressure, reduction/loss of smell) for ≥3 months, with 1 symptom required to be congestion/obstruction or nasal discharge; purulent mucus or obstructive edema or mucus in the middle meatus or ethmoid region on endoscopic examination; at least moderate symptoms despite use of topical steroids at conventional doses for ≥6 weeks; and at least moderate symptoms despite use (or previous use) of saline lavage for ≥6 weeks.
Efficacy was also evaluated with the Lund-Kennedy endoscopic scoring system, a validated approach to measurement of sinonasal cavity inflammatory disease, at each nasal endoscopic examination (47) . Lund-Kennedy scores include 5 components (polyposis, discharge, edema, scarring, and crusting), each graded on an ordinal scale from 0-2 for each side. Higher scores indicate worse disease. Efficacy assessments were also obtained directly from treated subjects using the Patient Global Impression of Change (PGIC). The PGIC scale is the most commonly used anchor-based method of assessing clinically important change based on patient input (48, 49) . The PGIC is particularly suited to capturing clinically meaningful change that makes a difference to the patient; it consists of 1 question rated on a 7-point Likert scale (49, 50) . In addition, a medical evaluation questionnaire as- 
Results
A total of 966 participants were screened, and 705 enrolled and received study drug (102 CRSwNP, 603 CRSsNP). Overall, 149 (27.5%) had a history of sinus surgery. Of 705 receiving study drug, 601 (85.2%) completed the study and 104 (14.8%) discontinued prematurely. Reasons for discontinuation included loss to follow-up (43 participants; 6.1%), AEs (22 participants, 3.1%; 14 deemed related by the study investigator), withdrawal of consent (20 participants; 2.8%), withdrawal due to protocol deviation (12 participants; 1.7%), other reasons (4 participants; 0.6%), and lack of efficacy (3 participants; 0.4%). Baseline characteristics are reported in Table 1 Table 2 ). Improvement in SNOT- 22 total scores exceeded the MCID of 8.9-12 (44, 45) and was not a function of isolated subscales; substantial improvement was reported on all subscales by patients with or without NP ( Table 3) .
The subset of patients with NP at study entry had notably lower baseline polyp grades (implying more superiorly/posteriorly located polyp tissue) than typically observed in CRSwNP treatment trials (mean baseline polyp grade 2.9) (22, 51, 52) . Nevertheless, of whom previously used corticosteroids and/or had prior sinonasal surgery. The EDS-FLU dose in this study was 372 µg BID, comparable to the EU-approved dose of fluticasone drops but higher than the equivalent dose studies of mometasone conventional inhaled spray (51, 52) . This allowed safety assessment at the highest approved dose, though in pivotal trials the efficacy of a lower dose (186 µg BID; comparable to the studied mometasone dose) was reasonably similar (39, 40) .
Previously published RCTs in patients with CRSwNP showed that EDS-FLU improves all four defining symptoms of CRS (congestion, rhinorrhea, facial pain/pressure, hyposmia), reduces NP grade, eliminates up to ≈30% of polyps in ≥1 nostril after 24 weeks of treatment, and results in SNOT-22 improvement similar in magnitude to reported improvement with endoscopic sinus surgery (39, 40) . This trial expands the evidence base and provides information from a large and diverse cohort enrolled with less restrictive entry criteria than typical for controlled pivotal trials.
Importantly, this study population comprised patients likely to be real-world candidates for EDS-FLU treatment (patients who continue to have symptoms despite prior use of conventional inhaled nasal steroids and/or history of sinus surgery).
In this study, patients with or without NP at baseline experienced substantial improvements in symptoms, QoL, functioning, and objective evidence of sinonasal inflammatory disease.
Improvements measured by SNOT-22 were comparable in magnitude for participants with or without NP, and all SNOT-22 subscales improved. The magnitude of improvement substantially exceeds previously reported clinically significant thresholds of 8.9-12 points and is comparable to the magnitude of improvement reported following endoscopic sinus surgery, although the treatment populations may differ (44, 45) .
Symptomatic improvement correlated with objective improvement in sinonasal inflammation, assessed using serial LundKennedy endoscopic scoring. In particular, nasal edema and discharge, both elevated at baseline, showed improvement with EDS-FLU. This substantiates that the improved intranasal deposition of anti-inflammatory drug with EDS-FLU is associated with improved symptoms and QoL.
PGIC values ≥6 ("much" or "very much" improvement) have been found to equate to a noticeable, worthwhile change that is meaningful to the patient (48, 49) . Despite the relatively refractory population entering the current study, a very high proportion of participants reported improvement at 3 months (90% improved; 73% "much" or "very much" improved). This finding is consistent with prior research (39) (40) (41) Current CRS treatment guidelines recommend topical nasal corticosteroids, usually administered using a conventional inhalation nasal spray, as first-line therapy (5, 6) . Alternate nonconventional delivery methods, mostly gravity-assisted, such as nasal drops and locally compounded high-volume medicated irrigation, have been studied to varying degrees but are subject to serious practical challenges, particularly when long-term compliance is necessary (23, 26, (31) (32) (33) . Considerations include difficulty with training and optimal head positions, control of local dose exposure, off-target gastrointestinal or lung exposure, time and effort associated with use, discomfort, poor dose control, and insurance coverage. For patients with milder symptoms or larger (easier to access) polyps, conventional inhaled nasal sprays offer some symptom benefit and have been shown to reduce polyp size (51) (52) (53) (54) . Interestingly, baseline polyp grade scores in registration studies for nasal spray mometasone (51, 52, 54) (and of EDS-FLU) (39, 40) ranged from 3.6 to 4.3; after 4 months of treatment, scores remained higher than or similar to the baseline polyp scores in this study (2.9) . Different anatomic barriers to delivering drug to polyp tissue of different grades and the nonlinear nature of the grading scale both accentuate the inappropriateness of comparing 'absolute' numerical changes across trials and the importance of considering baseline scores (55) . Indeed, several trials with conventional inhaled nasal sprays suggest that improvement in bilateral polyp grade (on a 0-6 scale) appears to plateau at an average score of ≈3 and does not improve further with longer treatment (22, 51, 52) . Furthermore, data from a longerterm study of conventional nasal spray suggests that smaller polyps may experience regrowth during such treatment (22) . This is not surprising because conventional inhaled steroid sprays are capable of reliably delivering locally-acting medication to the surface of large polyps that protrude far inferiorly or anteriorly, but do not continue to deliver steroid to the surface of polyps as they regress into the region of the OMC, where inflammation and associated polypoid tissue continue to obstruct sinuses (24) (25) (26) .
In this study, CRSwNP patients had a baseline polyp grade of only 2.9, and EDS-FLU produced a continually decreasing polyp grade, reaching 1.6 after 3 months; 63.0% of participants were observed to have ≥1-point improvement in NP score, and 46.7% of patients experienced complete polyp elimination in at least 1 nostril by study end. This progressive decrease in polyp gradeand elimination in some cases-is physiologically consistent with reliable long-term deposition of steroid on inflamed tissue, including the site of origin of most polyps in the OMC region.
We are unaware of similar improvement previously reported with other topical medical therapies.
Surgery is often offered to CRS patients who fail medical therapy (5, 6, 56, 57) . Revision surgery is also performed in a substantial minority of patients whose symptoms are not adequately addressed by the initial procedure and subsequent medical therapy (56, 57) . At baseline in this study, many patients had undergone previous surgery and/or had ongoing, significant symptoms despite use of conventional nasal steroids. However, comparatively few met this study's surgical indicator criteria, particularly those without polyps. Nevertheless, treatment was associated with a substantial reduction in the proportion of participants, with or without polyps, meeting surgical-indicator criteria.
Surgery is generally considered effective and is appropriate for many patients, but achieving disease control that delays or prevents surgery, or repeat surgery, may produce meaningful economic benefits.
EDS-FLU was generally well tolerated at the highest recommended dose and exhibited a safety profile consistent with previous intranasal corticosteroids that were studied for similar durations in similar populations (51, 52) . The safety profile was also consistent with previous reports from double blind placebo-controlled studies (39, 40) . The majority of AEs were local, mild in severity, and did not increase in frequency or severity with longer duration of use.
Most AEs observed in the nasal cavity resolved with continued use. No systemic AEs associated with systemic corticosteroid absorption, including glaucoma and subcapsular cataracts, were identified.
Strengths and Limitations
This is one of the largest studies conducted to date in patients with moderate-to-severe CRS (including both CRSwNP and CRSsNP) and is highly generalizable in the target clinical scenario: however, studies with low baseline scores as in this study (ie, consistent with polyps in the middle meatus, <3) have reported that polyp grade actually increases with placebo treatment (39, 42, (51) (52) (53) (54) 58) . In this study, the CRSsNP population met CRS symptom criteria and underwent endoscopy at baseline, but confirmatory sinus imaging was not required.
Conclusion
In summary, this study finds that EDS-FLU was associated with improvement in objective evidence of sinonasal inflammation, including elimination of edema in a substantial proportion of patients, along with improved symptoms, QoL, and functioning.
Similar benefits were reported in patients with or without NP at baseline and in patients switching directly from conventional inhaled nasal sprays. These data suggest that EDS-FLU is a helpful new tool in addressing this chronic and challenging disease and should be considered, before or after surgery, when optimizing medical care in patients with CRS.
